Related Experiment Video

Updated: Jul 2, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

RPN2 gene confers docetaxel resistance in breast cancer

Kimi Honma1, Kyoko Iwao-Koizumi, Fumitaka Takeshita

  • 1Section for Studies on Metastasis, Japanese National Cancer Center Research Institute, 1-1, Tsukiji, 5-chome, Chuo-ku, Tokyo 104-0045, Japan.

Nature Medicine
|August 30, 2008
PubMed

Insights

Ribophorin II (RPN2) downregulation enhances docetaxel efficacy in resistant breast cancer cells. Silencing RPN2 sensitizes cells to chemotherapy and reduces tumor growth, identifying RPN2 as a potential therapeutic target for overcoming drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Drug resistance in cancer, particularly to docetaxel in breast cancer, is a major cause of treatment failure.
  • Identifying molecular targets is crucial for developing novel therapeutic strategies against resistant cancers.

Purpose of the Study:

  • To investigate the regulatory network of docetaxel resistance in breast cancer cells.
  • To identify potential molecular targets for overcoming docetaxel resistance.

Main Methods:

  • Small interfering RNAs (siRNAs) were used to target 36 genes upregulated in docetaxel-nonresponsive breast cancer.
  • The efficacy of gene silencing was assessed by its ability to induce apoptosis in docetaxel-resistant MCF7-ADR cells.
  • In vivo studies utilized siRNA targeting RPN2 in drug-resistant tumor models.

Main Results:

  • Downregulation of ribophorin II (RPN2) most effectively induced apoptosis in docetaxel-resistant breast cancer cells.
  • RPN2 silencing reduced P-glycoprotein glycosylation and membrane localization, sensitizing cells to docetaxel.
  • In vivo administration of RPN2-specific siRNA significantly inhibited tumor growth in drug-resistant models.

Conclusions:

  • RPN2 silencing renders cancer cells hypersensitive to docetaxel.
  • RPN2 represents a promising new target for RNA interference-based therapies aimed at combating drug resistance in cancer.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...